Dr. Ann M. Navar, MD, PHD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 50
Licensed in Texas since 2020, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Duke University School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
TX license S8348 (first issued 2020; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ut of Texas Southwestern University Hospital - William P. Clements Jr. Dallas, TX
- Parkland Health & Hospital System Dallas, TX
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 50
- Services billed
- 91
- Patients’ average age
- 67
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 56 payments worth $95,117 in total to this clinician.
| Eli Lilly and Company | $38,681 |
|---|---|
| Novo Nordisk As | $32,386 |
| Merck Sharp & Dohme LLC | $12,470 |
| Esperion Therapeutics, Inc. | $6,600 |
| Novo Nordisk Inc | $3,533 |
| Janssen Scientific Affairs, LLC | $1,200 |
| Cleerly, Inc. | $234 |
| Amgen Inc. | $13.61 |
| Consulting Fee | $71,196 |
|---|---|
| Travel and Lodging | $15,860 |
| Compensation for services other than consulting (speaking, faculty) | $7,000 |
| Food and Beverage | $1,062 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk As Jan 1, 2025 | Consulting Fee Cardiovascular | $19,429 |
| Novo Nordisk As Jan 1, 2025 | Travel and Lodging Cardiovascular · travel to Barcelona, Spain · in-kind | $11,884 |
| Eli Lilly and Company Apr 8, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $9,450 |
| Eli Lilly and Company Jul 17, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $7,350 |
| Eli Lilly and Company Apr 4, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $4,900 |
| Merck Sharp & Dohme LLC Oct 8, 2025 | Consulting Fee | $4,480 |
| Eli Lilly and Company Apr 8, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $4,200 |
| Eli Lilly and Company Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,850 |
| Novo Nordisk Inc Nov 11, 2025 | Consulting Fee Cardiovascular | $3,533 |
| Eli Lilly and Company Apr 14, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,150 |
All 42 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 10, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $587 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $569 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $569 |
| Eli Lilly and Company Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $700 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting Fee | $2,880 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Travel and Lodging travel to New Orleans, LA | $150 |
| Eli Lilly and Company Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,850 |
| Eli Lilly and Company Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,450 |
| Novo Nordisk Inc Nov 11, 2025 | Consulting Fee Cardiovascular | $3,533 |
| Merck Sharp & Dohme LLC Nov 11, 2025 | Travel and Lodging CARDIOVASCULAR · travel to New Orleans, LA · in-kind | $172 |
| Merck Sharp & Dohme LLC Nov 10, 2025 | Travel and Lodging CARDIOVASCULAR · travel to New Orleans, LA · in-kind | $199 |
| Eli Lilly and Company Oct 22, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $450 |
| Eli Lilly and Company Oct 22, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $148 |
| Eli Lilly and Company Oct 22, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $115 |
| Merck Sharp & Dohme LLC Oct 8, 2025 | Consulting Fee | $4,480 |
| Esperion Therapeutics, Inc. Jul 31, 2025 | Consulting Fee NEXLIZET; NEXLETOL · ANTILIPEMIC AGENTS | $1,980 |
| Eli Lilly and Company Jul 17, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $7,350 |
| Esperion Therapeutics, Inc. Jul 8, 2025 | Consulting Fee NEXLIZET; NEXLETOL · ANTILIPEMIC AGENTS | $2,640 |
| Eli Lilly and Company Jun 20, 2025 | Travel and Lodging travel to CHICAGO, IL | $432 |
| Eli Lilly and Company Jun 20, 2025 | Travel and Lodging travel to CHICAGO, IL | $75.17 |
| Eli Lilly and Company Jun 20, 2025 | Travel and Lodging travel to CHICAGO, IL | $60.94 |
| Eli Lilly and Company Jun 20, 2025 | Travel and Lodging travel to CHICAGO, IL | $27.00 |
| Merck Sharp & Dohme LLC May 7, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $1,150 |
| Merck Sharp & Dohme LLC Apr 28, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $196 |
| Merck Sharp & Dohme LLC Apr 28, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $190 |
| Merck Sharp & Dohme LLC Apr 28, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $190 |
| Merck Sharp & Dohme LLC Apr 23, 2025 | Consulting Fee CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $575 |
| Eli Lilly and Company Apr 14, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,150 |
| Eli Lilly and Company Apr 8, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $9,450 |
| Eli Lilly and Company Apr 8, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $4,200 |
| Janssen Scientific Affairs, LLC Apr 7, 2025 | Consulting Fee | $1,200 |
| Eli Lilly and Company Apr 7, 2025 | Travel and Lodging travel to STAMFORD, TX · in-kind | $799 |
| Eli Lilly and Company Apr 7, 2025 | Travel and Lodging travel to STAMFORD, CT · in-kind | $217 |
| Eli Lilly and Company Apr 7, 2025 | Travel and Lodging travel to STAMFORD, TX · in-kind | $131 |
| Eli Lilly and Company Apr 7, 2025 | Travel and Lodging travel to STAMFORD, TX · in-kind | $131 |
| Eli Lilly and Company Apr 4, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $4,900 |
| Esperion Therapeutics, Inc. Apr 1, 2025 | Consulting Fee NEXLIZET; NEXLETOL · ANTILIPEMIC AGENTS | $1,980 |
| Merck Sharp & Dohme LLC Mar 28, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Chicago, IL Company’s descriptionProvided as part of a clinical research engagement. | $80.42 |
| Novo Nordisk As Jan 1, 2025 | Consulting Fee Cardiovascular | $19,429 |
| Novo Nordisk As Jan 1, 2025 | Travel and Lodging Cardiovascular · travel to Barcelona, Spain · in-kind | $11,884 |
| Novo Nordisk As Jan 1, 2025 | Travel and Lodging Cardiovascular · travel to Barcelona, Spain · in-kind | $395 |
| Novo Nordisk As Jan 1, 2025 | Travel and Lodging Cardiovascular · travel to Barcelona, Spain · in-kind | $394 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $179 in research payments for these studies, mostly to the institutions running them.
- Cardiovascular Multicenter OBservational Investigation of lipid care in the United States
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.